Global Alpha-1 Antitrypsin Deficiency Treatment Market Size, Share, Forecast Report, 2020-2027

The global Alpha-1 Antitrypsin Deficiency Treatment market garnered revenue around USD XX Billion in 2019 and projected to reach USD 2.5 Billion in 2027, with at a compound annual growth rate of 10.52% throughout the estimate period from 2020 to 2027.

Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency.

Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the growth of the global alpha-1 antitrypsin deficiency treatment market.

Strategic mergers & acquisitions are also projected to boost market growth with companies looking to strengthen their market positions, expand their product portfolios, and improve their brand images. For instance, on 3rd September 2019, Kamada Pharmaceuticals signed an agreement with Takeda Pharmaceutical Ltd for supply and distribution of Glassia, which is an alpha-1 proteinase inhibitor used for the treatment of alpha-1 antitrypsin deficiency.

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Alpha-1 Antitrypsin Deficiency Treatment market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Alpha-1 Antitrypsin Deficiency Treatment market growth.

The global Alpha-1 Antitrypsin Deficiency Treatment market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

Kamada Pharmaceuticals (Israel): Offers Glassia, an alpha-1 antitrypsin deficiency treatment drug. It also has inhalation AATD drug in Phase 2 clinical trials in the US and phase 3 clinical trials in Europe.

CSL Behring LLC (US): Leading provider of plasma-derived and recombinant therapeutic products for rare diseases such as AATD. Hosted the symposium about AATD treatment in Paris.

Grifols, S.A. (Spain): Offers the Grifols Prolastin -C Liquid (alpha-1 proteinase inhibitor) for the treatment of AATD since 2017.

Takeda Pharmaceutical Company Limited (Japan): Manufactures drugs for emphysema which is a main form of AATD.

GlaxoSmithKline plc (UK): The company offers bronchodilators for the treatment of AATD.

Boehringer Ingelheim GmbH (Germany): Manufacturer and distributor for bronchodilators.

AstraZeneca (UK): Offers bronchodilators such as the Bevespi Aerosphere inhalation aerosol for treatment of COPD associated with AATD.

Vectura Group plc (UK): Offers Ultibro Breezhaler dual bronchodilator.

Pfizer Inc. (US): Offers the Spiriva Handihaler bronchodilator for the treatment of COPD associated with AATD.

Mylan Inc. (US): Received FDA approval in November 2018 for YUPELRI, a long-acting muscarinic antagonist nebulized bronchodilator.

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Drugs

Alpha-1 Proteinase Inhibitor:

Bronchodilators:

Steroids:

Others:

By Route of Administration

Oral:

Intravenous:

Inhalation:

Others:

By Distribution Channel

Hospital Pharmacy:

Retail Pharmacy:

Online Stores:

Regional Analysis and Forecast



Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:



� North America

? U.S.

? Canada

� Europe

? Germany

? U.K.

? Italy

? France

? Rest of EU

� Asia Pacific

? China

? India

? Japan

? Southeast Asia

? Rest of APAC

� Central & South America

? Brazil

? Argentina

? Rest of Central & South America

� Middle East and Africa

? UAE

? Saudi Arabia

? Rest of MEA